Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC 50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P) , and induces cell apoptosis . Anticancer activity In Vitro Ceranib-2 (10 nM-10 µM; 72 hours; SKOV3 cells) treatment inhibits cell proliferation and/or survival with an IC 50 value of 0.73 μM. Ceranib-2 (0.75-1.5 µM; 48 hours; SKOV3 cells) treatment causes accumulation of cells in the sub-G1 (apoptosis), G2 and S (0.75 μM only) phases of the cell cycle, concomitant with reductions in the number of cells in G1 phase. Ceranib-2 produces a dose-dependent decrease in ceramidase activity, with 50% inhibition at 28 μM, induces the accumulation of multiple ceramide species, and decreases levels of sphingosine and S1P. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SKOV3 cells Concentration: 10 nM-10 µM Incubation Time: 72 hours Result: Cell proliferation and/or survival were inhibited with an IC 50 value of 0.73 μM for Ceranib-2. Cell Cycle AnalysisCell Line: SKOV3 cells Concentration: 0.75 μM, or 1.5 μM Incubation Time: 48 hours Result: Induced cell-cycle arrest and cell death. In Vivo Ceranib-2 (20-50 mg/kg; intraperitoneal injection; daily for 5 days per week; for 3 weeks; female Balb/c mice) treatment delays tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity . Intraperitoneal administration of 50 mg/kg Ceranib-2 results in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 μM at the 2 hr time point. Ceranib-2 appears to be cleared with a half-life of less than 2 hr . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Balb/c mice injected with JC murine mammary adenocarcinoma cells Dosage: 20 mg/kg or 50 mg/kg Administration: Intraperitoneal injection; daily for 5 days per week; for 3 weeks Result: Delayed tumor growth in a syngeneic tumor model. Form:Solid IC50& Target:IC50: 28 μM (Ceramidase)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Ceranib-2
Dangerous GoodsCAS number：1402830-75-4 molecular formula：C24H17NO3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1402830-75-4 | molecular formula | C24H17NO3 |
| molecular weight | 367.4 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
pictogram：
GHS07
Signal word：
Warning
Hazard Statement：
H413: 可能对水生生物造成长期的有害影响 H302: 吞食有害
Statement of Preventive Measures：
P273: 避免释放到环境中。 P501: 将内容物/容器处理到。。。 P264: 处理后要彻底洗手。 P270: 使用本产品时，请勿进食、饮水或吸烟。 P330: 漱口 P301+P317: 如果被吞咽：请寻求医疗帮助。
WGK Germany：
3
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
